الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Breast cancer is the most frequent cancer in women worldwide, and it is the main cause of cancer-related fatalities, followed by lung, colorectal, and cervical cancers. TNBC is the most aggressive out of all the molecular subtypes of breast cancer. It accounts for 15-20% of all breast cancers. It’s linked to a younger age of onset, a more aggressive clinical course and eventually a poor prognosis. This subtype of breast cancer is known for having a high probability of distant recurrences after adjuvant therapy and has a rapid progression on palliative chemotherapy in the metastatic setting.
Although breast cancer treatment options have improved, systemic therapies to inhibit metastasis are less effective. It is therefore essential to develop novel therapeutics for the control of breast cancer initiation and progression.
The emergence of non-coding RNAs (ncRNAs) as important regulators of gene expression, there are great opportunities for them to be evaluated as alternative treatments for the management of a variety of diseases, including breast cancer. In many cancers, selective expression of miRNAs enhanced the therapeutic drug resistance with the use of conventional chemotherapy. As a result, miRNAs are important for cancer progression and could be used as an alternative target for treating breast cancer and reversing treatment resistance.